{"transactions":[{"id":726182,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:05:13.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001581956-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000158195626000004/primarydocument.xml","form_type":"4"}},{"id":1107542,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:26:56.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004899","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218025004899/primarydocument.xml","form_type":"4"}},{"id":1467007,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:08:04.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005363","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218024005363/primarydocument.xml","form_type":"4"}},{"id":1846180,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:13:27.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005477","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218023005477/primarydocument.xml","form_type":"4"}},{"id":2223773,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-06-23T01:00:49.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":13.81,"exercise_date":"2023-06-21","expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-22-005320","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218022005320/primarydocument.xml","form_type":"4"}},{"id":2633819,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-14T20:52:43.000Z","date":"2021-07-13","kind":"grant","acquired":true,"shares":12530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors."}],"balance_after":12530,"derivative":{"exercise_price":9.4,"exercise_date":"2022-07-13","expiration_date":"2031-07-12","underlying":"Common Stock","underlying_shares":12530},"source":{"system":"sec-edgar","filing":"0001562180-21-004931","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218021004931/primarydocument.xml","form_type":"4"}},{"id":3491243,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-06-13T20:07:42.000Z","date":"2019-06-11","kind":"exercise","acquired":false,"shares":7218,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015."}],"balance_after":0,"derivative":{"exercise_price":2.3375,"expiration_date":"2022-04-05","underlying":"Common stock","underlying_shares":7218},"source":{"system":"sec-edgar","filing":"0001628280-19-007955","document":"wf-form4_156045644678438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000162828019007955/wf-form4_156045644678438.xml","form_type":"4"}},{"id":3491242,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-06-13T20:07:42.000Z","date":"2019-06-11","kind":"exercise","acquired":true,"shares":7218,"price":2.3375,"value":16872.075,"ownership":{"direct":true},"balance_after":33729,"source":{"system":"sec-edgar","filing":"0001628280-19-007955","document":"wf-form4_156045644678438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000162828019007955/wf-form4_156045644678438.xml","form_type":"4"}},{"id":3559273,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-04-09T20:59:31.000Z","date":"2019-04-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":39648,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-19-024105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/doc4.xml","form_type":"4"}},{"id":3559272,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-04-09T20:59:31.000Z","date":"2019-04-05","kind":"sale","acquired":false,"shares":599,"price":68.12,"value":40803.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $68.00 to $68.27. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":26511,"source":{"system":"sec-edgar","filing":"0001209191-19-024105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/doc4.xml","form_type":"4"}},{"id":3559271,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-04-09T20:59:31.000Z","date":"2019-04-05","kind":"sale","acquired":false,"shares":2401,"price":67.61,"value":162331.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $67.00 to $67.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":27110,"source":{"system":"sec-edgar","filing":"0001209191-19-024105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/doc4.xml","form_type":"4"}},{"id":3559270,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-04-09T20:59:31.000Z","date":"2019-04-05","kind":"exercise","acquired":true,"shares":3000,"price":39.76,"value":119280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":29511,"source":{"system":"sec-edgar","filing":"0001209191-19-024105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119024105/doc4.xml","form_type":"4"}},{"id":3606192,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-07T21:06:55.000Z","date":"2019-03-05","kind":"exercise","acquired":false,"shares":2572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":42648,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":2572},"source":{"system":"sec-edgar","filing":"0001209191-19-017738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/doc4.xml","form_type":"4"}},{"id":3606191,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-07T21:06:55.000Z","date":"2019-03-05","kind":"exercise","acquired":false,"shares":428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":11354,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":428},"source":{"system":"sec-edgar","filing":"0001209191-19-017738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/doc4.xml","form_type":"4"}},{"id":3606190,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-07T21:06:55.000Z","date":"2019-03-05","kind":"sale","acquired":false,"shares":200,"price":68.22,"value":13644.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $68.14 to $68.30. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":26511,"source":{"system":"sec-edgar","filing":"0001209191-19-017738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/doc4.xml","form_type":"4"}},{"id":3606189,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-07T21:06:55.000Z","date":"2019-03-05","kind":"sale","acquired":false,"shares":2600,"price":67.73,"value":176098.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $67.14 to $68.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":26711,"source":{"system":"sec-edgar","filing":"0001209191-19-017738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/doc4.xml","form_type":"4"}},{"id":3606188,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-07T21:06:55.000Z","date":"2019-03-05","kind":"sale","acquired":false,"shares":200,"price":66.45,"value":13290.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $66.05 to $66.85. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":29311,"source":{"system":"sec-edgar","filing":"0001209191-19-017738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/doc4.xml","form_type":"4"}},{"id":3606187,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-07T21:06:55.000Z","date":"2019-03-05","kind":"exercise","acquired":true,"shares":2572,"price":39.76,"value":102262.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":29511,"source":{"system":"sec-edgar","filing":"0001209191-19-017738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/doc4.xml","form_type":"4"}},{"id":3606186,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-07T21:06:55.000Z","date":"2019-03-05","kind":"exercise","acquired":true,"shares":428,"price":31.64,"value":13541.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":26939,"source":{"system":"sec-edgar","filing":"0001209191-19-017738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119017738/doc4.xml","form_type":"4"}},{"id":3623112,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-01T21:02:40.000Z","date":"2019-02-27","kind":"exercise","acquired":false,"shares":3080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":11782,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":3080},"source":{"system":"sec-edgar","filing":"0001209191-19-014933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/doc4.xml","form_type":"4"}},{"id":3623111,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-01T21:02:40.000Z","date":"2019-02-27","kind":"exercise","acquired":false,"shares":4154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":0,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":4154},"source":{"system":"sec-edgar","filing":"0001209191-19-014933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/doc4.xml","form_type":"4"}},{"id":3623110,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-01T21:02:40.000Z","date":"2019-02-27","kind":"exercise","acquired":false,"shares":1766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015."}],"balance_after":0,"derivative":{"exercise_price":0.47,"expiration_date":"2020-12-06","underlying":"Common stock","underlying_shares":1766},"source":{"system":"sec-edgar","filing":"0001209191-19-014933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/doc4.xml","form_type":"4"}},{"id":3623109,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-01T21:02:40.000Z","date":"2019-02-27","kind":"sale","acquired":false,"shares":9000,"price":65,"value":585000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":26511,"source":{"system":"sec-edgar","filing":"0001209191-19-014933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/doc4.xml","form_type":"4"}},{"id":3623108,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-01T21:02:40.000Z","date":"2019-02-27","kind":"exercise","acquired":true,"shares":3080,"price":31.64,"value":97451.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":35511,"source":{"system":"sec-edgar","filing":"0001209191-19-014933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/doc4.xml","form_type":"4"}},{"id":3623107,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-01T21:02:40.000Z","date":"2019-02-27","kind":"exercise","acquired":true,"shares":4154,"price":9.05,"value":37593.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":32431,"source":{"system":"sec-edgar","filing":"0001209191-19-014933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/doc4.xml","form_type":"4"}},{"id":3623106,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-03-01T21:02:40.000Z","date":"2019-02-27","kind":"exercise","acquired":true,"shares":1766,"price":0.47,"value":830.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":28277,"source":{"system":"sec-edgar","filing":"0001209191-19-014933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119014933/doc4.xml","form_type":"4"}},{"id":3631953,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted stock units","published_at":"2019-02-26T21:24:02.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":10000,"derivative":{"underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-013525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119013525/doc4.xml","form_type":"4"}},{"id":3631952,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-02-26T21:24:02.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":58.86,"expiration_date":"2029-02-22","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-013525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119013525/doc4.xml","form_type":"4"}},{"id":3645708,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted stock units","published_at":"2019-02-20T21:03:07.000Z","date":"2019-02-16","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":5500,"derivative":{"underlying":"Common stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001209191-19-011486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011486/doc4.xml","form_type":"4"}},{"id":3645707,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:03:07.000Z","date":"2019-02-19","kind":"tax_withholding","acquired":false,"shares":876,"price":58.03,"value":50834.28,"ownership":{"direct":true},"balance_after":26511,"source":{"system":"sec-edgar","filing":"0001209191-19-011486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011486/doc4.xml","form_type":"4"}},{"id":3645706,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:03:07.000Z","date":"2019-02-16","kind":"exercise","acquired":true,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":27387,"source":{"system":"sec-edgar","filing":"0001209191-19-011486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011486/doc4.xml","form_type":"4"}},{"id":3718958,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-12-26T21:39:36.000Z","date":"2018-12-21","kind":"exercise","acquired":false,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015."}],"balance_after":7218,"derivative":{"exercise_price":2.3375,"expiration_date":"2022-04-05","underlying":"Common stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-18-064102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118064102/doc4.xml","form_type":"4"}},{"id":3718957,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-12-26T21:39:36.000Z","date":"2018-12-21","kind":"exercise","acquired":true,"shares":20500,"price":2.3375,"value":47918.75,"ownership":{"direct":true},"balance_after":24637,"source":{"system":"sec-edgar","filing":"0001209191-18-064102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118064102/doc4.xml","form_type":"4"}},{"id":3771500,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-11-07T21:09:06.000Z","date":"2018-11-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":4154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-057556","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/doc4.xml","form_type":"4"}},{"id":3771499,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-11-07T21:09:06.000Z","date":"2018-11-05","kind":"sale","acquired":false,"shares":100,"price":71.42,"value":7142.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":50932,"source":{"system":"sec-edgar","filing":"0001209191-18-057556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/doc4.xml","form_type":"4"}},{"id":3771498,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-11-07T21:09:06.000Z","date":"2018-11-05","kind":"sale","acquired":false,"shares":700,"price":70.23,"value":49161.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $70.00 to $70.57. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":51032,"source":{"system":"sec-edgar","filing":"0001209191-18-057556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/doc4.xml","form_type":"4"}},{"id":3771497,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-11-07T21:09:06.000Z","date":"2018-11-05","kind":"sale","acquired":false,"shares":2200,"price":69.44,"value":152768.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $68.97 to $69.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":51732,"source":{"system":"sec-edgar","filing":"0001209191-18-057556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/doc4.xml","form_type":"4"}},{"id":3771496,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-11-07T21:09:06.000Z","date":"2018-11-05","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":53932,"source":{"system":"sec-edgar","filing":"0001209191-18-057556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118057556/doc4.xml","form_type":"4"}},{"id":3794346,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-10-09T20:09:34.000Z","date":"2018-10-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":7154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-054513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/doc4.xml","form_type":"4"}},{"id":3794345,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-09T20:09:34.000Z","date":"2018-10-05","kind":"sale","acquired":false,"shares":21,"price":71.77,"value":1507.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":50932,"source":{"system":"sec-edgar","filing":"0001209191-18-054513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/doc4.xml","form_type":"4"}},{"id":3794344,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-10-09T20:09:34.000Z","date":"2018-10-05","kind":"sale","acquired":false,"shares":1100,"price":71.05,"value":78155.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.61 to $71.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":50953,"source":{"system":"sec-edgar","filing":"0001209191-18-054513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/doc4.xml","form_type":"4"}},{"id":3794343,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-10-09T20:09:34.000Z","date":"2018-10-05","kind":"sale","acquired":false,"shares":979,"price":69.47,"value":68011.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $69.24 to $70.22. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":52053,"source":{"system":"sec-edgar","filing":"0001209191-18-054513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/doc4.xml","form_type":"4"}},{"id":3794342,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-10-09T20:09:34.000Z","date":"2018-10-05","kind":"sale","acquired":false,"shares":900,"price":68.56,"value":61704.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $68.13 to $69.05. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":53032,"source":{"system":"sec-edgar","filing":"0001209191-18-054513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/doc4.xml","form_type":"4"}},{"id":3794341,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-10-09T20:09:34.000Z","date":"2018-10-05","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":53932,"source":{"system":"sec-edgar","filing":"0001209191-18-054513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118054513/doc4.xml","form_type":"4"}},{"id":3821954,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-09-07T20:12:50.000Z","date":"2018-09-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":10154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-050043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118050043/doc4.xml","form_type":"4"}},{"id":3821953,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-09-07T20:12:50.000Z","date":"2018-09-05","kind":"sale","acquired":false,"shares":100,"price":84.38,"value":8438.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-050043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118050043/doc4.xml","form_type":"4"}},{"id":3821952,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-09-07T20:12:50.000Z","date":"2018-09-05","kind":"sale","acquired":false,"shares":2260,"price":83.17,"value":187964.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $83.00 to $83.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57296,"source":{"system":"sec-edgar","filing":"0001209191-18-050043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118050043/doc4.xml","form_type":"4"}},{"id":3821951,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-09-07T20:12:50.000Z","date":"2018-09-05","kind":"sale","acquired":false,"shares":640,"price":82.52,"value":52812.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $82.00 to $82.98. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":59556,"source":{"system":"sec-edgar","filing":"0001209191-18-050043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118050043/doc4.xml","form_type":"4"}},{"id":3821950,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-09-07T20:12:50.000Z","date":"2018-09-05","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":60196,"source":{"system":"sec-edgar","filing":"0001209191-18-050043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118050043/doc4.xml","form_type":"4"}},{"id":3847356,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-10T21:20:47.000Z","date":"2018-07-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":16154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-046269","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118046269/doc4a.xml","form_type":"4/A","original_submission_date":"2018-07-09"}},{"id":3847355,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-10T21:19:57.000Z","date":"2018-06-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":19154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-046268","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118046268/doc4a.xml","form_type":"4/A","original_submission_date":"2018-06-07"}},{"id":3847354,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-10T21:19:15.000Z","date":"2018-05-23","kind":"exercise","acquired":false,"shares":15177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":14862,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":15177},"source":{"system":"sec-edgar","filing":"0001209191-18-046266","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118046266/doc4a.xml","form_type":"4/A","original_submission_date":"2018-05-29"}},{"id":3847353,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-10T21:18:37.000Z","date":"2018-05-07","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":22154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-046265","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118046265/doc4a.xml","form_type":"4/A","original_submission_date":"2018-05-08"}},{"id":3847352,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-10T21:17:47.000Z","date":"2018-04-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":25154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-046264","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118046264/doc4a.xml","form_type":"4/A","original_submission_date":"2018-04-09"}},{"id":3847351,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-10T21:16:47.000Z","date":"2018-03-28","kind":"exercise","acquired":false,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015."}],"balance_after":27718,"derivative":{"exercise_price":2.34,"expiration_date":"2022-04-05","underlying":"Common stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001209191-18-046262","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118046262/doc4a.xml","form_type":"4/A","original_submission_date":"2018-03-30"}},{"id":3847350,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-10T21:16:47.000Z","date":"2018-03-28","kind":"exercise","acquired":false,"shares":37,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015."}],"balance_after":1766,"derivative":{"exercise_price":0.4675,"expiration_date":"2020-12-06","underlying":"Common stock","underlying_shares":37},"source":{"system":"sec-edgar","filing":"0001209191-18-046262","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118046262/doc4a.xml","form_type":"4/A","original_submission_date":"2018-03-30"}},{"id":3849626,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-08-08T20:14:20.000Z","date":"2018-08-06","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":13154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-045820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118045820/doc4.xml","form_type":"4"}},{"id":3849625,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-08-08T20:14:20.000Z","date":"2018-08-06","kind":"sale","acquired":false,"shares":600,"price":80.87,"value":48522.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $80.64 to $81.01. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-045820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118045820/doc4.xml","form_type":"4"}},{"id":3849624,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-08-08T20:14:20.000Z","date":"2018-08-06","kind":"sale","acquired":false,"shares":2100,"price":80.15,"value":168315.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $79.53 to $80.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57796,"source":{"system":"sec-edgar","filing":"0001209191-18-045820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118045820/doc4.xml","form_type":"4"}},{"id":3849623,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-08-08T20:14:20.000Z","date":"2018-08-06","kind":"sale","acquired":false,"shares":300,"price":78.32,"value":23496.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $78.01 to $78.53. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":59896,"source":{"system":"sec-edgar","filing":"0001209191-18-045820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118045820/doc4.xml","form_type":"4"}},{"id":3849622,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-08-08T20:14:20.000Z","date":"2018-08-06","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":60196,"source":{"system":"sec-edgar","filing":"0001209191-18-045820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118045820/doc4.xml","form_type":"4"}},{"id":3871072,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-07-09T20:08:28.000Z","date":"2018-07-05","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":16154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-041982","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118041982/doc4.xml","form_type":"4"}},{"id":3871071,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-07-09T20:08:28.000Z","date":"2018-07-05","kind":"sale","acquired":false,"shares":300,"price":84.32,"value":25296.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $84.07 to $84.69. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-041982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118041982/doc4.xml","form_type":"4"}},{"id":3871070,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-07-09T20:08:28.000Z","date":"2018-07-05","kind":"sale","acquired":false,"shares":2700,"price":83.41,"value":225207.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $83.01 to $83.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57496,"source":{"system":"sec-edgar","filing":"0001209191-18-041982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118041982/doc4.xml","form_type":"4"}},{"id":3871069,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-07-09T20:08:28.000Z","date":"2018-07-05","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":60196,"source":{"system":"sec-edgar","filing":"0001209191-18-041982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118041982/doc4.xml","form_type":"4"}},{"id":3901544,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-06-07T20:02:41.000Z","date":"2018-06-05","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":19154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-036320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118036320/doc4.xml","form_type":"4"}},{"id":3901543,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-06-07T20:02:41.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":939,"price":94.28,"value":88528.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $94.13 to $94.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-036320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118036320/doc4.xml","form_type":"4"}},{"id":3901542,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-06-07T20:02:41.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":1259,"price":93.27,"value":117426.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $92.96 to $93.79. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":58135,"source":{"system":"sec-edgar","filing":"0001209191-18-036320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118036320/doc4.xml","form_type":"4"}},{"id":3901541,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-06-07T20:02:41.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":802,"price":92.45,"value":74144.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $91.90 to $92.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":59394,"source":{"system":"sec-edgar","filing":"0001209191-18-036320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118036320/doc4.xml","form_type":"4"}},{"id":3901540,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-06-07T20:02:41.000Z","date":"2018-06-05","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":60196,"source":{"system":"sec-edgar","filing":"0001209191-18-036320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118036320/doc4.xml","form_type":"4"}},{"id":3915355,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-05-29T10:11:05.000Z","date":"2018-05-23","kind":"exercise","acquired":true,"shares":15177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":14862,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":15177},"source":{"system":"sec-edgar","filing":"0001209191-18-033646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118033646/doc4.xml","form_type":"4"}},{"id":3915354,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-05-29T10:11:05.000Z","date":"2018-05-23","kind":"sale","acquired":false,"shares":15177,"price":90,"value":1365930.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-033646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118033646/doc4.xml","form_type":"4"}},{"id":3915353,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-05-29T10:11:05.000Z","date":"2018-05-23","kind":"exercise","acquired":true,"shares":15177,"price":31.64,"value":480200.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":72373,"source":{"system":"sec-edgar","filing":"0001209191-18-033646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118033646/doc4.xml","form_type":"4"}},{"id":3942436,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-05-08T20:08:22.000Z","date":"2018-05-07","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":22154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-028538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118028538/doc4.xml","form_type":"4"}},{"id":3942435,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-05-08T20:08:22.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":3000,"price":81.81,"value":245430.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $81.30 to $82.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-028538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118028538/doc4.xml","form_type":"4"}},{"id":3942434,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-05-08T20:08:22.000Z","date":"2018-05-07","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":60196,"source":{"system":"sec-edgar","filing":"0001209191-18-028538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118028538/doc4.xml","form_type":"4"}},{"id":3966951,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-04-09T20:09:52.000Z","date":"2018-04-05","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":25154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-024317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118024317/doc4.xml","form_type":"4"}},{"id":3966950,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-04-09T20:09:52.000Z","date":"2018-04-05","kind":"sale","acquired":false,"shares":500,"price":77.17,"value":38585.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $76.70 to $77.64. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-024317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118024317/doc4.xml","form_type":"4"}},{"id":3966949,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-04-09T20:09:52.000Z","date":"2018-04-05","kind":"sale","acquired":false,"shares":800,"price":76.17,"value":60936.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $75.69 to $76.64. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":57696,"source":{"system":"sec-edgar","filing":"0001209191-18-024317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118024317/doc4.xml","form_type":"4"}},{"id":3966948,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-04-09T20:09:52.000Z","date":"2018-04-05","kind":"sale","acquired":false,"shares":400,"price":75.04,"value":30016.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $74.68 to $75.38. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":58496,"source":{"system":"sec-edgar","filing":"0001209191-18-024317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118024317/doc4.xml","form_type":"4"}},{"id":3966947,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-04-09T20:09:52.000Z","date":"2018-04-05","kind":"sale","acquired":false,"shares":1300,"price":73.9,"value":96070.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $73.41 to $74.39. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":58896,"source":{"system":"sec-edgar","filing":"0001209191-18-024317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118024317/doc4.xml","form_type":"4"}},{"id":3966946,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-04-09T20:09:52.000Z","date":"2018-04-05","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":60196,"source":{"system":"sec-edgar","filing":"0001209191-18-024317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118024317/doc4.xml","form_type":"4"}},{"id":3978745,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-03-30T20:18:28.000Z","date":"2018-03-28","kind":"exercise","acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015."}],"balance_after":27718,"derivative":{"exercise_price":2.34,"expiration_date":"2022-04-05","underlying":"Common stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001209191-18-022211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118022211/doc4.xml","form_type":"4"}},{"id":3978744,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-03-30T20:18:28.000Z","date":"2018-03-28","kind":"exercise","acquired":true,"shares":37,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015."}],"balance_after":1766,"derivative":{"exercise_price":0.4675,"expiration_date":"2020-12-06","underlying":"Common stock","underlying_shares":37},"source":{"system":"sec-edgar","filing":"0001209191-18-022211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118022211/doc4.xml","form_type":"4"}},{"id":3978743,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-03-30T20:18:28.000Z","date":"2018-03-28","kind":"exercise","acquired":true,"shares":4100,"price":2.34,"value":9594.0,"ownership":{"direct":true},"balance_after":57196,"source":{"system":"sec-edgar","filing":"0001209191-18-022211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118022211/doc4.xml","form_type":"4"}},{"id":3978742,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-03-30T20:18:28.000Z","date":"2018-03-28","kind":"exercise","acquired":true,"shares":37,"price":0.4675,"value":17.2975,"ownership":{"direct":true},"balance_after":53096,"source":{"system":"sec-edgar","filing":"0001209191-18-022211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118022211/doc4.xml","form_type":"4"}},{"id":4008118,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-03-07T21:10:32.000Z","date":"2018-03-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":28154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-017686","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118017686/doc4.xml","form_type":"4"}},{"id":4008117,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-03-07T21:10:32.000Z","date":"2018-03-05","kind":"sale","acquired":false,"shares":1100,"price":84.1,"value":92510.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $83.66 to $84.65. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":53059,"source":{"system":"sec-edgar","filing":"0001209191-18-017686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118017686/doc4.xml","form_type":"4"}},{"id":4008116,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-03-07T21:10:32.000Z","date":"2018-03-05","kind":"sale","acquired":false,"shares":1100,"price":83.21,"value":91531.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.65 to $83.57. The\nreporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,\nto provide full information regarding the number of shares sold at each separate price."}],"balance_after":54159,"source":{"system":"sec-edgar","filing":"0001209191-18-017686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118017686/doc4.xml","form_type":"4"}},{"id":4008115,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-03-07T21:10:32.000Z","date":"2018-03-05","kind":"sale","acquired":false,"shares":400,"price":82.04,"value":32816.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.53 to $82.36. The\nreporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,\nto provide full information regarding the number of shares sold at each separate price."}],"balance_after":55259,"source":{"system":"sec-edgar","filing":"0001209191-18-017686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118017686/doc4.xml","form_type":"4"}},{"id":4008114,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-03-07T21:10:32.000Z","date":"2018-03-05","kind":"sale","acquired":false,"shares":400,"price":80.93,"value":32372.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.49 to $81.35. The\nreporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,\nto provide full information regarding the number of shares sold at each separate price."}],"balance_after":55659,"source":{"system":"sec-edgar","filing":"0001209191-18-017686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118017686/doc4.xml","form_type":"4"}},{"id":4008113,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-03-07T21:10:32.000Z","date":"2018-03-05","kind":"exercise","acquired":true,"shares":3000,"price":9.05,"value":27150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":56059,"source":{"system":"sec-edgar","filing":"0001209191-18-017686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118017686/doc4.xml","form_type":"4"}},{"id":4047480,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted stock units","published_at":"2018-02-20T21:02:26.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8250,"derivative":{"underlying":"Common stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001209191-18-011242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118011242/doc4.xml","form_type":"4"}},{"id":4047479,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-02-20T21:02:26.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":33000,"derivative":{"exercise_price":77.7,"expiration_date":"2028-02-15","underlying":"Common stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001209191-18-011242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118011242/doc4.xml","form_type":"4"}},{"id":4072106,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-02-07T21:05:16.000Z","date":"2018-02-05","kind":"exercise","acquired":false,"shares":2936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares."}],"balance_after":31154,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-30","underlying":"Common stock","underlying_shares":2936},"source":{"system":"sec-edgar","filing":"0001209191-18-008108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118008108/doc4.xml","form_type":"4"}},{"id":4072105,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock options (right to buy)","published_at":"2018-02-07T21:05:16.000Z","date":"2018-02-05","kind":"exercise","acquired":false,"shares":64,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015."}],"balance_after":1803,"derivative":{"exercise_price":0.4675,"expiration_date":"2020-12-06","underlying":"Common stock","underlying_shares":64},"source":{"system":"sec-edgar","filing":"0001209191-18-008108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118008108/doc4.xml","form_type":"4"}},{"id":4072104,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-02-07T21:05:16.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":400,"price":78.03,"value":31212.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $77.63 to $78.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":53059,"source":{"system":"sec-edgar","filing":"0001209191-18-008108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118008108/doc4.xml","form_type":"4"}},{"id":4072103,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-02-07T21:05:16.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":701,"price":76.76,"value":53808.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.44 to $77.20. The\nreporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,\nto provide full information regarding the number of shares sold at each separate price."}],"balance_after":53459,"source":{"system":"sec-edgar","filing":"0001209191-18-008108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118008108/doc4.xml","form_type":"4"}},{"id":4072102,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-02-07T21:05:16.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":1100,"price":75.7,"value":83270.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.31 to $76.26. The\nreporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,\nto provide full information regarding the number of shares sold at each separate price."}],"balance_after":54160,"source":{"system":"sec-edgar","filing":"0001209191-18-008108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118008108/doc4.xml","form_type":"4"}},{"id":4072101,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2018-02-07T21:05:16.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":799,"price":74.89,"value":59837.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $74.16 to $75.06. The\nreporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,\nto provide full information regarding the number of shares sold at each separate price."}],"balance_after":55260,"source":{"system":"sec-edgar","filing":"0001209191-18-008108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118008108/doc4.xml","form_type":"4"}}],"next_cursor":"2018-02-07T21:05:16.000000Z,4072101"}